Objective
Leaky gut / increased intestinal permeability, IBD (mild–moderate), dysbiosis with inflammation, post-NSAID gastritis, reflux with mucosal damage, gluten sensitivity, etc.
This stack is designed to pair well with BHRT when indicated (Lesson 2B), but here we are only counting peptides, not hormones
"Direct shipping without issues is only guaranteed within the United States and Mexico. For all other countries, the buyer assumes full responsibility once the shipment is handed over to the courier (FedEx/DHL), including customs clearance and local compliance."
BPC-157 (Oral) : The “Body Protection Compound.” When taken orally (especially as a stable salt like Arginate), it survives gastric acid to heal the stomach lining, esophagus, and intestinal mucosa locally.
KPV (Oral): The anti-inflammatory fragment of $\alpha$-MSH. Oral delivery is often used here to treat intestinal candidiasis (yeast) and calm inflammation in the colon (Colitis/IBD).
Larazotide (AT-1001) : A peptide specifically engineered to act as a Zonulin Antagonist. Zonulin is the protein that triggers “tight junctions” in the gut to open (causing leaky gut). Larazotide helps lock these junctions closed. It has been in Phase 3 clinical trials for Celiac disease.
LL-37 1 Unit: The antimicrobial peptide. Included here likely to “scrub” the gut of pathogenic bacteria or biofilms (dysbiosis).
Protocol mechanism:
BPC-157 (Oral): The “Body Protection Compound.” When taken orally (especially as a stable salt like Arginate), it survives gastric acid to heal the stomach lining, esophagus, and intestinal mucosa locally.
KPV (Oral): The anti-inflammatory fragment of $\alpha$-MSH. Oral delivery is often used here to treat intestinal candidiasis (yeast) and calm inflammation in the colon (Colitis/IBD).
Larazotide (AT-1001): A peptide specifically engineered to act as a Zonulin Antagonist. Zonulin is the protein that triggers “tight junctions” in the gut to open (causing leaky gut). Larazotide helps lock these junctions closed. It has been in Phase 3 clinical trials for Celiac disease.
LL-37: The antimicrobial peptide. Included here likely to “scrub” the gut of pathogenic bacteria or biofilms (dysbiosis).
